Maxim Group analyst Jason McCarthy maintained a Buy rating on Aprea Therapeutics (APRE – Research Report) on May 14 and set a price target of $10.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Jason McCarthy has given his Buy rating due to a combination of factors related to Aprea Therapeutics’ ongoing clinical programs and financial position. The company is making significant progress in its synthetic lethality programs, particularly with ATRN-119 and APR-1051, which are advancing through their respective clinical trials. The ATRN-119 program, targeting ATR, is notable for its continuous dosing and positive safety profile, distinguishing it from other ATR inhibitors that have faced toxicity issues.
Additionally, Aprea’s financial health, with a cash runway extending into the second quarter of 2026, supports its ongoing research and development efforts. Despite recent market challenges affecting microcap biotech stocks, McCarthy believes that Aprea’s differentiated assets and strong management team position the company well for future success. The potential for establishing recommended Phase 2 doses for both ATRN-119 and APR-1051 by 2026 further reinforces the Buy rating, as these developments could lead to significant advancements in the treatment of advanced solid tumors.
APRE’s price has also changed dramatically for the past six months – from $3.350 to $1.530, which is a -54.33% drop .